I'll have to let someone smarter than me decipher the Deferred Share Unit Plan and its implications.
However, the Royalty Preferred Share Amendment seems like a good move. Instead of the Royalty Preferred Shares ONLY receiving a dividend calculated based on a percentage of net revenue earned from the sale or licensing of compounds that elevate apoAI, it is now being proposed to include ANY pharmaceutical product in which the Corporation holds an intellectual property right.
We do know that they are getting ready to move forward with at least 1 new compound. This adjustment to the Royalty Preferred Shares may be a way to ensure that these new compound(s) are included in the RSP arrangement even if they don't affect apoAI. If and when a sale or licensing does happen with one of these new compounds, this would be a huge benefit for holders of the RSPs (owners of Zenith Capital Corp).
BearDownAZ
